A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Heat-labile enterotoxin E coli (Primary)
Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
Focus Pharmacodynamics
Sponsors Intercell USA; Valneva USA

11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
09 Sep 2008 Planned end date changed from 1 Jun 2008 to 1 Aug 2008, according to ClinicalTrials.gov.
08 Sep 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com